Information Provided By:
Fly News Breaks for March 3, 2015
BSX
Mar 3, 2015 | 08:02 EDT
After Boston Scientific (BSX) announced a definitive agreement to acquire Endo's (ENDP) AMS urology portfolio for up to $1.65B, Wells Fargo thinks the portfolio fits well into the company's existing urology business, while the company will be able to accelerate the growth of the portfolio. The firm raised its price target range on Boston Scientific to $19-$20 from $17.50-$18.00. It keeps an Outperform rating on the shares.
News For BSX From the Last 2 Days
BSX
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BSX
BSX
BSX
BSX
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.